open access

Vol 88, No 10 (2017)
Research paper
Published online: 2017-10-31
Get Citation

DNA methyltransferase inhibitors influence on the DIRAS3 and STAT3 expression and in vitro migration of ovarian and breast cancer cells

Ewa Maria Nowak1, Marta Poczęta1, Dominik Bieg1, Ilona Bednarek1
DOI: 10.5603/GP.a2017.0099
·
Pubmed: 29192415
·
Ginekol Pol 2017;88(10):543-551.
Affiliations
  1. Department of Biotechnology and Genetic Engineering, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, ul. Jedności 8, 41-200 Sosnowiec, Poland

open access

Vol 88, No 10 (2017)
ORIGINAL PAPERS Gynecology
Published online: 2017-10-31

Abstract

Objectives: Downregulation of DIRAS3 (DIRAS family, GTP-binding Ras-like 3) is related to ovarian and breast cancer progression. A possible mechanism that silences this gene is the promoter region DNA methylation. The potential reversibility of this epigenetic mechanism makes it more attractive candidate for new mode of cancer treatment. DIRAS3 regulates cell cycle, tumor dormancy and inhibits cancer cell growth and motility, all of which may indirectly depend on interaction with STAT3 (Signal Transducer and Activator of Transcription 3) classified as a potential oncogene. The restoration of DIRAS3 expression could inhibit cell proliferation and invasiveness.

Material and methods: Human ovarian carcinoma cell line (A2780) and human breast cancer cell line (MCF7) were exposed to two DNA methyltransferase inhibitors (DNMTi): decitabine (5-aza-2’-deoxycytidine) [25 μM and 12.5 μM] and RG108 [150 μM and 100 μM]. In vitro migration changes of cancer cells were examined with wound healing assay. After 7 days of DNMTi treatment cells were harvested and DNA and RNA was isolated. The methylation status of the promoter sequences of DIRAS3 and STAT3 genes was determined using methylation specific PCR (MS-PCR). Level of target genes’ expression was quantified using quantitative reverse transcription PCR (QRT-PCR).

Results and conclusions: The in vitro wound healing assay showed changes in the migration rate of both adherent cell lines after DNMTi treatment compared to the untreated cells. Relative balance between methylated and unmethylated variants of DIRAS3 after MS-PCR was shifted towards unmethylated version after DNMTi treatment in A2780 cells. Statistically significant dose dependent effect of decitabine and RG108 on DIRAS3 expression in A2780 cells was observed.

Abstract

Objectives: Downregulation of DIRAS3 (DIRAS family, GTP-binding Ras-like 3) is related to ovarian and breast cancer progression. A possible mechanism that silences this gene is the promoter region DNA methylation. The potential reversibility of this epigenetic mechanism makes it more attractive candidate for new mode of cancer treatment. DIRAS3 regulates cell cycle, tumor dormancy and inhibits cancer cell growth and motility, all of which may indirectly depend on interaction with STAT3 (Signal Transducer and Activator of Transcription 3) classified as a potential oncogene. The restoration of DIRAS3 expression could inhibit cell proliferation and invasiveness.

Material and methods: Human ovarian carcinoma cell line (A2780) and human breast cancer cell line (MCF7) were exposed to two DNA methyltransferase inhibitors (DNMTi): decitabine (5-aza-2’-deoxycytidine) [25 μM and 12.5 μM] and RG108 [150 μM and 100 μM]. In vitro migration changes of cancer cells were examined with wound healing assay. After 7 days of DNMTi treatment cells were harvested and DNA and RNA was isolated. The methylation status of the promoter sequences of DIRAS3 and STAT3 genes was determined using methylation specific PCR (MS-PCR). Level of target genes’ expression was quantified using quantitative reverse transcription PCR (QRT-PCR).

Results and conclusions: The in vitro wound healing assay showed changes in the migration rate of both adherent cell lines after DNMTi treatment compared to the untreated cells. Relative balance between methylated and unmethylated variants of DIRAS3 after MS-PCR was shifted towards unmethylated version after DNMTi treatment in A2780 cells. Statistically significant dose dependent effect of decitabine and RG108 on DIRAS3 expression in A2780 cells was observed.

Get Citation

Keywords

DNA methylation, DNA methyltransferases inhibitors, DIRAS3 expression, STAT3 expression, ovarian cancer, breast cancer

About this article
Title

DNA methyltransferase inhibitors influence on the DIRAS3 and STAT3 expression and in vitro migration of ovarian and breast cancer cells

Journal

Ginekologia Polska

Issue

Vol 88, No 10 (2017)

Article type

Research paper

Pages

543-551

Published online

2017-10-31

DOI

10.5603/GP.a2017.0099

Pubmed

29192415

Bibliographic record

Ginekol Pol 2017;88(10):543-551.

Keywords

DNA methylation
DNA methyltransferases inhibitors
DIRAS3 expression
STAT3 expression
ovarian cancer
breast cancer

Authors

Ewa Maria Nowak
Marta Poczęta
Dominik Bieg
Ilona Bednarek

References (30)
  1. Dai Z, Kosuri K, Otterson GA. Mechanisms of DNA demethylating drugs against cancer progression. In: Esteller M. ed. DNA Methylation, Epigenetics and Metastasis. Springer, United States 2005: 244–267.
  2. Subramaniam D, Thombre R, Dhar A, et al. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol. 2014; 4: 80.
  3. Earp MA, Cunningham JM. DNA methylation changes in epithelial ovarian cancer histotypes. Genomics. 2015; 106(6): 311–321.
  4. Győrffy B, Bottai G, Fleischer T, et al. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. Int J Cancer. 2016; 138(1): 87–97.
  5. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16 Spec No 1: R50–R59.
  6. Luo RZ, Peng H, Xu F, et al. Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochim Biophys Acta. 2001; 1519(3): 216–222.
  7. Rosen DG, Wang L, Jain AN, et al. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res. 2004; 10(19): 6559–6566.
  8. Li J, Cui G, Sun Lu, et al. STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer. Oncol Rep. 2013; 30(1): 165–170.
  9. Lu Z, Bast RC. The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adh Migr. 2013; 7(2): 232–236.
  10. http://www.uniprot.org/uniprot/O95661#expression.
  11. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 2005; 65(3): 939–947.
  12. Muthu K, Panneerselvam M, Topno NS, et al. Structural perspective of ARHI mediated inhibition of STAT3 signaling: an insight into the inactive to active transition of ARHI and its interaction with STAT3 and importinβ. Cell Signal. 2015; 27(4): 739–755.
  13. Nishimoto A, Yu Y, Lu Z, et al. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res. 2005; 65(15): 6701–6710.
  14. http://www.onkologia-online.pl/medicine.
  15. Gros C, Fahy J, Halby L, et al. DNA methylation inhibitors in cancer: recent and future approaches. Biochimie. 2012; 94(11): 2280–2296.
  16. Fahy J, Jeltsch A, Arimondo PB. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat. 2012; 22(12): 1427–1442.
  17. Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013; 33(8): 2989–2996.
  18. Heerboth S, Lapinska K, Snyder N, et al. Use of epigenetic drugs in disease: an overview. Genet Epigenet. 2014; 6: 9–19.
  19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402–408.
  20. Bai H, Cao D, Yang J, et al. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med. 2016; 20(4): 581–593.
  21. Li Y, Shi Li, Han C, et al. Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells. Tumour Biol. 2012; 33(5): 1403–1410.
  22. Yu Y, Fujii S, Yuan J, et al. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci. 2003; 983: 268–277.
  23. Huang S, Chang InS, Lin W, et al. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep. 2009; 30(3): 159–168.
  24. Barrow TM, Barault L, Ellsworth RE, et al. Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer. Int J Cancer. 2015; 137(3): 537–547.
  25. Lu Z, Luo RZ, Peng H, et al. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res. 2006; 12(8): 2404–2413.
  26. Han Z, Feng J, Hong Z, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 2013; 435(2): 188–194.
  27. Chen MY, Liao WSL, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011; 117(19): 4424–4438.
  28. Feng W, Marquez RT, Lu Z, et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008; 112(7): 1489–1502.
  29. Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics. 2006; 1(1): 7–13.
  30. Gil L, Mądry K, Komarnicki M. Mechanizmy działania leków hipometylujących w zespołach mielodysplastycznych. Hematologia. 2012; 3(2): 120–126.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl